Source comparison
Pharmacological Distinction: Receptor Bypass Versus Axis Stimulation
The fundamental mechanistic distinction between IGF-1 LR3 and CJC-1295 lies in where each compound intervenes in the GH-IGF-1 axis. CJC-1295 (with DAC modification) binds the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary, stimulating GH
This comparison does not assign a generated winner or score.
- The fundamental mechanistic distinction between IGF-1 LR3 and CJC-1295 lies in where each compound intervenes in the GH-IGF-1 axis. CJC-1295 (with DAC modification) binds the GHRH receptor (GHRHR) on somatotroph cells in the anterior pituitary, stimulating GH pulse secretion and amplitude. GH then travels to the liver, activating GHR-Jak2-STAT5b signalling, upregulating IGF-1 synthesis (predominantly IGF-1Ea/1Eb splice variants), and inducing hepatic IGFBP-3 and ALS (acid-labile subunit) to form the circulating 150kDa ternary complex that extends IGF-1 half-life to 12-15 hours in the systemic circulation.
- IGF-1 LR3 bypasses this entire axis. The 13-amino acid N-terminal extension (MFPAMPLLSLFVN) and the Glu³→Arg³ substitution reduce IGFBP binding affinity by >1000-fold compared to native IGF-1, while preserving IGF-1R binding (Kd ~1-2nM). This means IGF-1 LR3 reaches skeletal muscle IGF-1R directly in its pharmacologically active unbound form, with a plasma half-life of ~20 hours driven by the IGFBP bypass rather than ternary complex formation. In practical research terms: CJC-1295 generates an endogenous GH pulse → hepatic IGF-1 synthesis → ternary complex formation → slow IGF-1R activation in peripheral tissues; IGF-1 LR3 generates direct IGF-1R activation within 30-60 minutes of administration.